GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Conclusions/interpretationOur study provides novel evidence for the beneficial effect of GLP-1R agonists on WFS1-deficient human pancreatic beta cells and neurons, suggesting that these drugs may be considered as a treatment for individuals with Wolfram syndrome.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Brain | Byetta | Diabetes | Diabetes Insipidus | Diabetes Mellitus | Endocrinology | Genetics | Insulin | Mitochondrial Disease | Neurology | Pancreas | Stem Cell Therapy | Stem Cells | Study